Back to top

BioMarin price target lowered to $62 from $66 at RBC Capital

RBC Capital analyst Luca Issi lowered the firm’s price target on BioMarin (BMRN) to $62 from $66 and keeps a Sector Perform rating on the shares as...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)